Last reviewed · How we verify
Sensitive Eyes Rewetting Drops
Sensitive Eyes Rewetting Drops, marketed by the University of Alabama at Birmingham, is a currently available product in the ophthalmic care segment. The key composition patent is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Sensitive Eyes Rewetting Drops |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses (NA)
- Direct Application of Systane Complete to Contact Lenses (PHASE4)
- A 2-week Clinical Comparison of SYSTANE® Ultra to Sensitive Eyes Rewetting Drops in Contact Lens Wearing Patients.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |